Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market.
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.
Ampersand Biomedicines has emerged from stealth mode with a new CEO, and aims to shake up oncology and immunology with a new tissue-specific approach to targeting medicines.
Emerging Company Profile: BioAge has Phase Ib proof-of-concept data in age-related muscle loss and is gearing up for its first Phase II study, but will need fresh cash or a partner for a potential weight loss-related muscle loss study.
These are interesting times for Mironid, a Glasgow-based biotech developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease, a life-threatening hereditary condition.
The founder and MD of investment bank Candle Partners reflects on key pharma M&A trends over the years and the shape of things to come including private equity action and how family-owned firms are weighing monetization and diversification options.
CEO of Enzene Biosciences weighs in on the impact of Medicare negotiations in the US on the biosimilars market even as a US filing is planned for a Prolia biosimilar. In the interview, he says Enzene “is not afraid or concerned” over ongoing litigation with Merck KGaA over an Erbitux biosimilar in India, adding that new modalities like ADCs are being “seriously” considered.
Mariana Oncology closed a $175m series A venture capital round to fund its first clinical trial, for MC-339 in small-cell lung cancer, as well as its manufacturing and pipeline-building activities.
Dr Reddy's Laboratories' co-chairman and MD, GV Prasad, talks about his conversations with late founder Dr Anji Reddy, the company’s ‘Horizon 2’ strategy, pricing expectations for CAR-T cell therapies, the promise of the China market, how Indian owner-managed pharma firms are figuring out ways to deal with succession aspects and his new book.
A French biotech led by Philip Janiak, former head of cardiovascular research at Sanofi, is looking to bring therapies to heart failure subpopulations with high unmet needs.
Within a month of obtaining its global first approval in China, Hua Medicine's dorzagliatin is already available in hospitals. What was behind the successful launch of the first-in-class diabetes agent, what are reimbursement plans and how will local commercialization partner Bayer help? Founder and CEO Li Chen sits down to discuss these and other strategies.
Boehringer Ingelheim's head of innovation Michel Pairet tells Scrip that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers.
Emergex CEO and ex-research director at the University of Oxford, Thomas Rademacher, spoke with Scrip about the myth of the “Wuhan virus” and why synthetic T-cell adaptive vaccines are expected to be superior to RNA/mRNA ones. More partners are being sought for additional delivery mechanisms, the founder of the UK-based, clinical-stage biotech says in this podcast interview.
Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.
Putting aside access issues for Leqvio, Novartis has presented data showing that the small interfering RNA directed PCSK9 twice-a-year injection provides consistent low-density lipoprotein cholesterol reduction over six years and more.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.